Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation

NCT03452592 is registered in ClinicalTrials.gov with Allist Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03452592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03452592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation
Lead sponsor
Allist Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2018
Completion date
March 14, 2024
Enrollment
220 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nsclc patients with t790m